Regeneron price target raised to $800 from $740 at Cantor Fitzgerald

Cantor Fitzgerald analyst Carter Gould raised the firm’s price target on Regeneron (REGN) to $800 from $740 and keeps an Overweight rating on the shares. The Q4 call was uneventful, with focus remaining on the ongoing LAG-3 metastatic melanoma trial, which appears more likely to read out in Q2 than Q1, the analyst tells investors in a research note. While the pipeline seems undervalued at current prices, expectations for the fianlimab data may be overstated, with a more realistic stock move of mid-single digits, the firm says.